MIMS summary of Bempedoic acid (Nilemdo), a new oral treatment option for patients with raised cholesterol
Available as Nilemdo and as fixed-dose combination (Nustendi) with ezetimibe, for treatment of primary hypercholesterolaemia/mixed dyslipidaemia. It inhibits ATP citrate lyase, which is involved in cholesterol synthesis, and in contrast to statins its action is liver-specific.
Source:
Monthly Index of Medical Specialities
SPS commentary:
DRAFT NICE guidance does not recommend bempedoic acid within its marketing authorisations, for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in adults, as the cost-effectiveness estimates for bempedoic acid with ezetimibe are not what NICE normally considers an acceptable use of NHS resources.